Humira Biosimilars Could Reshape The Market

Editor’s note: This analysis is a collaboration between Mercer and Oliver Wyman.

There has been no shortage of biosimilar development and commercialization in the US over the past few years. More than 20 biosimilar versions of brand products have launched since 2015 when the Food and Drug Administration approved Zarxio, a drug used to reduce the risk of infection in patients receiving chemotherapy. The drugs cut across a range of therapeutic areas — oncology, oncology supportive care, immunology, diabetes, and ophthalmology. Despite the number of product launches, biosimilar adoption in the US has been a mixed bag, especially compared to Europe. For example, pegfilgrastim biosimilars captured roughly 40% volume market share...